<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Glycemic and body weight control are two outstanding goals in the treatment of patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> that often are not appropriately achieved </plain></SENT>
<SENT sid="1" pm="."><plain>This observational study evaluates whether treatment by quality controlled <z:mp ids='MP_0002055'>diabetes</z:mp> centers generates an improvement in this regard and focuses on associations with different therapies </plain></SENT>
<SENT sid="2" pm="."><plain>Data of 9.294 type 2 diabetic patients (mean age 66.9±11.6 years, mean <z:mp ids='MP_0002055'>diabetes</z:mp> duration 12.4±9.2 years) from 103 German <z:mp ids='MP_0002055'>diabetes</z:mp> centers were assessed by a standardized, prospective, computer-based <z:mp ids='MP_0002055'>diabetes</z:mp> care and outcome documentation system (DPV-Wiss-database) </plain></SENT>
<SENT sid="3" pm="."><plain>Therapeutic concepts included lifestyle intervention (n=1.813), oral <z:chebi fb="0" ids="35526">antidiabetics</z:chebi> (OAD, n=1.536), insulin (n=4.504) and insulin plus OAD (n=1.441) </plain></SENT>
<SENT sid="4" pm="."><plain>HbA1c and body weight were compared before and after a stable therapeutical period of 1.07±0.3 years </plain></SENT>
<SENT sid="5" pm="."><plain>Change in HbA1c (%): <z:hpo ids='HP_0000001'>all</z:hpo> patients 7.4±1.6-7.0±1.3, lifestyle intervention 7.5±1.9-6.9±1.5, OAD 6.7±1.1-6.5±1.0, insulin 7.6±1.6-7.2±1.4, insulin plus OAD 7.5±1.5-7.2±1.3; each p≤0.05 </plain></SENT>
<SENT sid="6" pm="."><plain>Change in body weight (kg): <z:hpo ids='HP_0000001'>all</z:hpo> patients +0.08±0.07, n. s.; lifestyle intervention -0.28±0.20, OAD -0.56±0.13, each p&lt;0.05 [metfomin -0.77±0.21, <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> drugs -0.75±0.34, each p&lt;0.05; <z:chebi fb="0" ids="50864">glitazones</z:chebi> +0.62±0.70, α-glucosidase inhibitors -0.22±0.76, each n. s.], insulin +0.27±0.10, insulin plus OAD +0.63±0.14, each n. s </plain></SENT>
<SENT sid="7" pm="."><plain>In summary, lifestyle, <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="26831">sulfonylurea</z:chebi> drug treatment resulted in HbA1c-values below 7.0% plus a significant weight reduction </plain></SENT>
<SENT sid="8" pm="."><plain>Insulin treatment-associated concepts resulted in HbA1c-values slightly above 7.0% without body weight alterations </plain></SENT>
<SENT sid="9" pm="."><plain>These "real life" data underline that a specialised and quality controlled <z:mp ids='MP_0002055'>diabetes</z:mp> care is able to achieve significant treatment results even in patients with disease progression and a high proportion of insulin therapies </plain></SENT>
</text></document>